|1.||Fullerton, Natasha E: 1 article (11/2005)|
|2.||Babich, John: 1 article (11/2005)|
|3.||Mairs, Robert J: 1 article (11/2005)|
|4.||Zalutsky, Michael R: 1 article (11/2005)|
|5.||Boyd, Marie: 1 article (11/2005)|
|6.||Kirk, David: 1 article (11/2005)|
|7.||Pimlott, Sally L: 1 article (11/2005)|
|8.||Ross, Susan C: 1 article (11/2005)|
|1.||Urinary Bladder Neoplasms (Bladder Cancer)
10/15/1994 - "In conclusion, these results have demonstrated that [211At]MABG is considerably more cytotoxic than [131I]MIBG and that [211At]MABG could have great potential as a radiotherapeutic agent for the treatment of neuroblastoma."
08/01/1996 - "A paired-label biodistribution was performed in athymic mice bearing SK-N-SH human neuroblastoma xenografts to compare the tissue uptake of meta-[211At]astatobenzylguanidine ([211At]MABG) and [131I]MIBG. "
01/01/1995 - "We conclude that the uptake capacity of medulloblastoma cell lines for [131I]MIBG uptake in vitro, while lower than that seen in SK-N-SH neuroblastoma cells, is sufficient to permit [211At]MABG to be used with significant therapeutic effectiveness."
06/15/1994 - "Norepinephrine and desipramine (DMI) decreased [211At]MABG uptake in SK-N-SH human neuroblastoma cells. "
08/01/1996 - "These results suggest such strategies might be useful for improving [211At]MABG tumor-to-normal tissue ratios."
08/01/1996 - "Pretreatment of mice with unlabeled MIBG increased tumor uptake of [211At]MABG by 1.5-fold while reducing uptake in heart and several other normal tissues. "
08/01/1996 - "Desipramine reduced tumor uptake of [211At] MABG by 43%, suggesting that its accumulation was related to the specific uptake-1 mechanism. "
08/01/1996 - "Significantly higher (p < 0.05) uptake of [211At]MABG was seen in tumor (3.8 +/- 0.8% ID/g vs. 3.1 +/- 0.7% ID/g at 8 h) compared to [131I]MIBG. "
|2.||N-acetyltalosaminuronic acid (NAT)
|1.||Heterologous Transplantation (Xenotransplantation)